Loading...
Loading...
Jefferies initiated coverage on Supernus Pharmaceuticals
SUPN with a Buy rating and a $13.00 price target.
Jefferies commented, "With two recently approved epilepsy drugs (each ~$250M peak), pipeline optionality and little binary risk, SUPN offers a compelling risk/reward with only ~$175M EV.Launch expectations have dropped precipitously and although consensus seems low on 2013 expenses, based on our conversations with
high-prescribing neurologists, we think the Q1 launch of Oxtellar XR will be surprisingly strong, and drives our $13 target."
Supernus Pharmaceuticals closed at $7.48 on Monday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in